The Bevacizumab Biosimilar Market growth continues to accelerate as oncology and ophthalmology sectors increasingly embrace cost-effective alternatives to the reference biologic for anti-angiogenic therapy. With bevacizumab being a cornerstone treatment for multiple solid tumors including colorectal, lung, breast, and glioblastoma, alongside expanding off-label use in age-related macular...